Table II.

Multivariate Cox Regression Analyses Including the Category Associated with the Airway Basal Cell (BC) Signature

	HR	95% C.I.	p
Age	1.07	1.03–1.11	<0.002
Gender	1.14	0.58–2.22	>0.7
Smoking status	1.27	0.46–3.51	>0.6
Pathological stage	3.81	2.01–7.22	<0.001
Lepidic pattern	1.23	0.25–6.09	>0.8
Adjuvant therapy	0.87	0.36–2.15	>0.7
Airway BC signature	1.59	1.14–2.22	<0.008

Note: In the multivariate analyses, age (continuous variable), gender (male vs female), smoking status (never vs ever smoker), pathological stage (I vs II to III) based on 6th edition TNM staging [36], pathological feature (adenocarcinoma with lepidic pattern (formarly bronchioloalveolar carcinoma) vs other adenocarcinoma), adjuvant therapy (no vs yes) and airway BC signature (BC-low vs BC-high adenocarcinoma) were included as factors. Adjuvant chemotherapy referred to systemic chemotherapy performed in pre- and/or post surgery, including adjuvant chemotherapy (n=20), adjuvant chemoradiotherapy (n=3), induction chemotherapy (n=4), and induction chemotherapy and adjuvant chemoradiotherapy (n=1).

Abbreviations: HR: hazard ratio for overall survival, CI; confidence interval, N.A: not available